Clinical Trial News and Research

RSS

Obeticholic acid improves liver health in people with nonalcoholic steatohepatitis

An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the National Institutes of Health. The FLINT study found that people with nonalcoholic steatohepatitis (NASH) who took obeticholic acid (OCA) had improved liver health during that period, including decreased inflammation and fat in the liver and decreased body weight versus people receiving a placebo. OCA was also associated with increases in itching and total cholesterol.

7 Nov 2014

MMRF initiative aims to speed up evaluation of new investigational drugs for multiple myeloma

The Multiple Myeloma Research Foundation today announced an initiative designed to accelerate the evaluation of new investigational therapies for multiple myeloma (MM).

6 Nov 2014

D-LIVER project aims to help patients with chronic liver disease

A European ICT for Health project aims to improve the quality of life of patients with chronic liver disease, by developing a remote support system to monitor their condition at home.

6 Nov 2014

NIH boosts funding for first large-scale clinical trial aimed at identifying drugs for Alzheimer's

The National Institutes of Health has boosted funding for the first large-scale clinical trial aimed at identifying drugs to stop or slow Alzheimer's disease in people destined to get the debilitating illness.

6 Nov 2014

Discovery Laboratories reports net loss of $11.3 million for third quarter 2014

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the third quarter ended September 30, 2014, as well as recent business updates.

6 Nov 2014

Dual intragastric balloon procedure shows promise for people with obesity

After six months, people with intragastric balloons in their stomachs lost more than twice their excess weight, compared to people who tried to lose weight under a medically supervised diet and exercise program alone, according to new research from a randomized clinical trial presented here at ObesityWeek 2014, the largest international event focused on the basic science, clinical application and prevention and treatment of obesity.

6 Nov 2014

Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

Introducing competing "biosimilar" versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the United States by $44 billion over the next decade, according to new analysis from the RAND Corporation.

6 Nov 2014

Asthma patients using behavioral therapy can improve lung health over the long-term

Asthma patients taught to habitually resist the urge to take deep breaths when experiencing symptoms were rewarded with fewer symptoms and healthier lung function, according to a new study from Southern Methodist University, Dallas.

6 Nov 2014

Non-injectable vaccine may provide long-term protection against deadly Ebola virus

A potentially breathable, respiratory vaccine in development has been shown to provide long-term protection for non-human primates against the deadly Ebola virus, as reported this week in the online edition of the journal Molecular Pharmaceutics.

5 Nov 2014

Common drug could become the future standard of care for HE patients

A common drug used to clean a person's bowels before a colonoscopy could become the future standard of care for patients with acute hepatic encephalopathy (HE), a mental disorientation problem that affects up to one in two cirrhosis patients.

4 Nov 2014

Study: Tonsil removal for children with sleep apnea decreases asthma severity

Surgical removal of the tonsils and adenoids in children suffering from sleep apnea is associated with decreased asthma severity, according to the first large study of the connection, published in the journal PLOS Medicine.

4 Nov 2014

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca and Pharmacyclics, Inc. today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors.

4 Nov 2014

Ruthigen enrolls first patient in Phase 1/2 clinical trial of RUT58-60

Ruthigen, Inc., announced today enrollment of the first patient in a Randomized, Double-Blind Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery.

4 Nov 2014

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2014.

4 Nov 2014

Inventiva’s IVA337 receives EMA COMP positive opinion on orphan drug designation for SSc treatment

Inventiva, a drug discovery company that focuses on therapeutic approaches involving transcription factors and epigenetic targets, today announces that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has given a positive opinion on the designation of IVA337 as an orphan medicinal product.

4 Nov 2014

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Merck Sharp & Dohme Ltd. MSD (known as Merck & Co., Inc. in the United States and Canada), today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection.

4 Nov 2014

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014

Nasal vaccine shows promise against Ebola virus

A nasal vaccine in development by researchers at The University of Texas at Austin has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a small pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long-lasting, which could have significant global implications in controlling future outbreaks.

4 Nov 2014

Epicure project: an interview with Frédéric Cren

Epicure is a project led by Inventiva and Institut Curie that aims to deliver pre-clinical candidates on two novel epigenetic targets that have been selected due to their potential to activate immune responses against cancer cells. In addition one of these two targets has potential in respiratory indications such as asthma or COPD.

3 Nov 2014

APBI with proton therapy less costly than other traditional treatments for early stage breast cancer

In terms of duration of treatment and cost, patients with early stage breast cancer may benefit from accelerated partial breast irradiation (APBI) with proton therapy versus whole breast irradiation (WBI), according to new research from The University of Texas MD Anderson Proton Therapy Center.

3 Nov 2014

Clinical Trial News and Research

Obeticholic acid improves liver health in people with nonalcoholic steatohepatitis

MMRF initiative aims to speed up evaluation of new investigational drugs for multiple myeloma

D-LIVER project aims to help patients with chronic liver disease

NIH boosts funding for first large-scale clinical trial aimed at identifying drugs for Alzheimer's

Discovery Laboratories reports net loss of $11.3 million for third quarter 2014

Dual intragastric balloon procedure shows promise for people with obesity

Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

Asthma patients using behavioral therapy can improve lung health over the long-term

Non-injectable vaccine may provide long-term protection against deadly Ebola virus

Common drug could become the future standard of care for HE patients

Study: Tonsil removal for children with sleep apnea decreases asthma severity

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

Ruthigen enrolls first patient in Phase 1/2 clinical trial of RUT58-60

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Inventiva’s IVA337 receives EMA COMP positive opinion on orphan drug designation for SSc treatment

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

Nasal vaccine shows promise against Ebola virus

Epicure project: an interview with Frédéric Cren

APBI with proton therapy less costly than other traditional treatments for early stage breast cancer

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery